The Oncology Institute Rebrands as Starling Oncology

Rhea-AI Summary

Starling Oncology (Nasdaq: STLN), formerly The Oncology Institute ("TOI"), announced a corporate rebrand to “Starling Oncology, Inc.™.” The company’s common stock will begin trading on Nasdaq under the new ticker symbol STLN on August 4, 2026, replacing “TOI.” According to the company, the new name reflects its evolution into an integrated oncology platform, while patients, payers, and providers are expected to experience no changes to phone numbers, portals, or points of contact and no disruption to care during the transition.

Argus Aug 3 session 3 alerts

+5.56% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – TOI

$486.62M Market Cap

In the Aug 3 session, TOI gained 5.56%, reflecting a notable positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. Historical event 1078806 had a 6.62% 24-ho...

Analysis

The stock moved +5.6% in the session following this news. Historical event 1078806 had a 6.62% 24-hour price reaction. Against that record, a strong positive response to this rebrand would remain a market-data observation, not evidence of operating change; low short positioning is a sourced risk.

Key Figures

Ticker effective date: August 4, 2026

Ticker effective date

August 4, 2026

STLN begins trading on Nasdaq, replacing TOI

Historical Context

5 past events · Latest: Jul 27

5 events

1. Jul 27

   Earnings date notice

   24h Move

   +4.2%

   Company announced its Q2 2026 results release and conference call schedule.

2. Jul 07

   Strategic refinancing

   24h Move

   +6.6%

   Refinancing repaid an $86 million convertible note using debt and cash.

3. May 26

   Conference participation

   24h Move

   +0.0%

   Chief medical officer scheduled to discuss value-based specialty care at APG conference.

4. May 13

   Investor conference

   24h Move

   +1.5%

   Executives scheduled a fireside chat at an institutional investor conference.

5. May 07

   Q1 earnings report

   24h Move

   -1.7%

   Revenue grew 41.2%, while net loss narrowed and guidance remained largely unchanged.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”

CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.”

“We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that we have a better solution for both payers and the patients who trust us with accessible, outcomes-focused, high-quality medical care," said Dan Virnich, MD, MBA, FACHE, Chief Executive Officer of Starling Oncology. "Starling Oncology is a name that reflects our scale and our continued upward trajectory as an organization. Like starlings in flight, our coordinated delivery model emphasizes accessibility and teamwork that defines our commitment to community-based cancer care. Our name is changing, but our mission remains steadfast: delivering high-quality, patient-centered cancer care to the communities we serve, with a focused ambition to help solve the cost crisis in oncology."

The rebrand marks an important milestone in the Company's continued growth and reflects its evolution beyond a traditional oncology practice into an integrated oncology platform serving patients, providers, and health plans across multiple markets.

As the Company rebrands, patients, payers and providers can expect the same phone numbers, portal access, and points of contact throughout the transition, with no disruption to care.

About Starling Oncology:
Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with leading oncology organizations. With more than 400 employed and network clinicians and more than 100 clinics and network locations across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information, visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.

Contacts:
Media
ICR Healthcare
StarlingPR@icrhealthcare.com

Investors
ICR Healthcare
StarlingIR@icrhealthcare.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did The Oncology Institute (TOI) announce for its Nasdaq listing on August 3, 2026?

The Oncology Institute announced a rebrand to Starling Oncology, Inc.™ and a ticker change to STLN. According to the company, its common stock will start trading under the new symbol on Nasdaq beginning August 4, 2026, replacing the previous “TOI” ticker.

When will Starling Oncology start trading under the new ticker symbol STLN on Nasdaq?

Starling Oncology’s common stock will begin trading on Nasdaq under the ticker STLN on August 4, 2026. According to the company, this change only affects the symbol, with the stock continuing to trade on Nasdaq while replacing the former “TOI” ticker.

Does the Starling Oncology (formerly TOI) rebrand affect patient care or access to services?

The rebrand is not expected to affect patient care or access to services. According to the company, patients, payers, and providers should see the same phone numbers, portal access, and points of contact, with no disruption to care during the Starling Oncology transition.

Why did The Oncology Institute change its name to Starling Oncology (STLN)?

The Oncology Institute changed its name to Starling Oncology to reflect its growth and integrated oncology platform. According to the company, the new brand emphasizes coordinated, accessible, community-based cancer care and aligns with its mission to deliver outcomes-focused, high-quality, value-based oncology services.

What does the Starling Oncology (Nasdaq: STLN) rebrand mean for TOI and TOIIW shareholders?

For shareholders, the main change is the common stock ticker switching from TOI to STLN on Nasdaq. According to the company, the rebrand marks a milestone in its evolution but is not described as changing care delivery access, contacts, or existing operational touchpoints.

How does Starling Oncology describe its business model after rebranding from The Oncology Institute (TOI)?

Starling Oncology describes itself as one of the largest value-based oncology groups in the United States. According to the company, it has evolved beyond a traditional practice into an integrated oncology platform serving patients, providers, and health plans across multiple markets with coordinated, technology-enabled care.